The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of early bone metastases and outcomes of the bone predominant metastatic urothelial carcinoma (BP mUC) phenotype.
 
Ariel Ann Nelson
No Relationships to Disclose
 
Matthew David Wright
No Relationships to Disclose
 
Ali Raza Khaki
Stock and Other Ownership Interests - Pfizer; Procter & Gamble; Walgreens Boots Alliance
 
Leonidas Nikolaos Diamantopoulos
No Relationships to Disclose
 
Ravi Kumar Kyasaram
No Relationships to Disclose
 
Behtash Nezami
No Relationships to Disclose
 
Scott Dawsey
No Relationships to Disclose
 
Krupen Patel
No Relationships to Disclose
 
Cheryl Eitman
No Relationships to Disclose
 
Gregory MacLennan
No Relationships to Disclose
 
Petros Grivas
Consulting or Advisory Role - AstraZeneca; Biocept; Bristol-Myers Squibb; Clovis Oncology; Driver, Inc; EMD Serono; Foundation Medicine; Genentech; HERON; Janssen; Merck; Pfizer; QED Therapeutics; Seagen
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncogenex (Inst); Pfizer (Inst)
 
Prateek Mendiratta
No Relationships to Disclose
 
Lee Evan Ponsky
No Relationships to Disclose
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Research Funding - Merck Sharp & Dohme